Stempeutics Research signs out-licensing deal with Cipla

17 Sep 2019 Evaluate

Stempeutics Research has signed an out-licensing deal with Cipla for novel stem cell product 'Stempeucel-DFU' for treating non-healing diabetic foot ulcer. The deal consists of upfront payment and various milestones-based payments.

Under the agreement, Cipla will get exclusive marketing rights for five years in India for the diabetic foot ulcer (DFU) product. Stempeutics will manufacture and supply the product to Indian company.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1517.20 5.10 (0.34%)
12-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1794.30
Dr. Reddys Lab 1279.65
Cipla 1517.20
Zydus Lifesciences 929.05
Lupin 2114.10
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×